AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

Rhea-AI Summary

Amyris, a synthetic biotechnology company, has appointed Ana Dutra to its Board of Directors, effective January 21, 2022. With over 30 years of experience in global acquisitions and growth strategies, Dutra's expertise is expected to enhance shareholder value. CEO John Melo expressed optimism about her contributions, highlighting her leadership and operational depth. Dutra's background includes significant roles at major corporations, as well as experience in digital technology and ESG initiatives. This appointment comes as Amyris aims to leverage its Lab-to-Market platform for sustainable product innovation.

Positive

• Ana Dutra brings over 30 years of leadership and operational expertise, which could positively impact company's growth strategies.
• Her experience in M&A and digital transformation may enhance Amyris's competitive positioning.

Negative

• New Board member may imply a shift in strategic direction, raising concerns about continuity.
• Potential gaps in experience regarding specific industry challenges could pose risks.

EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market^TM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022.

"We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly relevant experience leading several global acquisitions and post-merger integrations as well as implementing accelerated growth strategies. We look forward to her contributions as we continue to execute our strategy and enhance value for Amyris shareholders."

Ms. Dutra is an experienced CEO, business advisor and corporate board director of publicly traded, private, and family-owned corporations, and non-profit organizations. She is a Latina leader with over 30 years of experience in P&L management, deal structuring, digital technology, business growth and C-Level business advisory in over 25 countries. Ana is fluent in English, French, Spanish, and Portuguese. She has deep experience in ESG, digital technology, e-commerce, ERP systems and has a CERT Certification in Cybersecurity Oversight by Carnegie Mellon University and the National Association of Corporate Directors.

As a CEO, Ana Dutra has led several global and cross-border acquisitions, joint ventures, partnership agreements and M&A integrations. In her own tenure as CEO and P&L leader with companies such as IBM, CSC, Marsh & McLennan, Accenture and Korn/ Ferry International, Ms. Dutra created several $500+ million global businesses through the combination of organic growth, global acquisitions and joint ventures, innovative go-to-market approaches and incorporation of technology and digital transformation of services and products.

Ms. Dutra holds an MBA from Kellogg at Northwestern University, a Master's in Economics from Pontificia Universidade do Rio de Janeiro, and a Juris Doctor from Universidade do Rio de Janeiro.

"I am very excited about joining the Amyris Board at this pivotal time in the company's growth," commented Ms. Dutra. "I look forward to working with my Board colleagues and the Company's management team to best leverage the tremendous assets it has developed to continue to bring diversified and sustainable products that make a positive impact on people and planet."

About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market^TM operating platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-announces-appointment-of-ana-dutra-to-board-of-directors-301469290.html

SOURCE Amyris, Inc.

FAQ

Who is Ana Dutra and what is her role at Amyris?

Ana Dutra is the newly appointed independent member of the Amyris Board of Directors, effective January 21, 2022, bringing extensive experience in leadership and M&A.

What expertise does Ana Dutra bring to Amyris?

Dutra has over 30 years of experience in operational leadership, global acquisitions, and business growth strategies, valuable for Amyris's objectives.

How might Ana Dutra's appointment affect Amyris's strategy?

Her background in digital technology and accelerated growth strategies may influence Amyris's approach towards sustainable product innovation.

When did Ana Dutra join the Amyris Board of Directors?

Ana Dutra officially joined the Amyris Board of Directors on January 21, 2022.

What are the anticipated benefits of Ana Dutra's leadership at Amyris?

Her expertise in leading global acquisitions and operational growth could enhance shareholder value and strengthen business strategies.